Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nighttime blood sugar spikes linked to fatty liver in type 1 diabetes?

NCT ID NCT05933018

Knowledge-focused Sponsor: HaEmek Medical Center, Israel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers want to know whether high blood sugar at night and early morning relates to fatty liver in people with type 1 diabetes. The study includes 100 adults with type 1 diabetes who use an insulin pump and a continuous glucose monitor. Participants are split into two groups based on whether they have nighttime high blood sugar. Everyone receives a liver scan to check for fat and stiffness, and researchers compare the groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If a link is found, it could help doctors identify who with type 1 diabetes faces fatty liver risk and guide earlier monitoring.
What could go wrong
This observational study cannot prove cause and effect, and the findings may not apply to people who do not use insulin pumps or glucose sensors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * type 1 diabetes patients * C- PEPTIDE level \<0.6 * continuous glucose monitoring system * insulin pump users Exclusion Criteria: * pregnancy * type 2 diabetes * non-pump or sensor users * unwilling to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatty liver TYPE1DIABETES

Contacts and locations

Locations

  • Emek Medical Center

    Afula, Israel/Zaphon, 1834160, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.